01Market Overview

Most U.S. benchmarks traded under pressure as risk sentiment continued to sour for AI-linked exposure. More selling in the beleaguered Chinese stock market spilled over into markets abroad, while government bond yields retreated for a second week and earnings reports were strong.

Ahead of more IPOX® earnings, IPO acquirers tracked by GINDEX® (GNDX) recorded a stellar relative week, with earnings and IPO M&A fever driving a big breakout in select health care stocks.

02U.S. Markets

The IPOX® 100 U.S. (IPXO), the U.S. IPO benchmark, declined 0.48% to +3.38% YTD last week, with the portfolio remaining under pressure after a failed attempt toward midweek to retake the key 200-trading-day average.

In what continues to be a mirror image of much of last year, equally weighted returns diverged sharply from the index, with 58% of holdings recording a positive week and an average (median) return of +1.11% (+1.00%).

We note big declines in heavyweights GE Vernova (GEV US: −11.53%), an electrification leader, and storage device maker Sandisk (SNDK US: −4.72%) drove much of the weakness, while stellar earnings failed to sustain the strength in industrial SpaceX (SPCX US: +1.00%).

In focus / Health care

VeraDermics in the spotlight

VeraDermics (MANE) vs. serial IPO acquirer Eli Lilly (LLY).

+27.53%MANE · weekly return

We note another big week for VeraDermics (MANE US: +27.53%), a New Haven, CT-based clinical-stage biopharma working on the next frontier in health care: treating hair loss. The stock has now gained +716% since its March 2026 IPO.

Source: Bloomberg; IPOX®

03International Markets

Desolate sentiment for China-linked exposure (CNI: −4.48% to −19.74% YTD) and profit-taking in Japan (IPJP: −4.54% to +52.36% YTD) weighed on the IPOX® International (IPXI: −3.28% to +5.93% YTD), while the IPOX® 100 Europe (IPOE: −1.25% to −1.53% YTD) fell less than the European market last week.

Big losses in Chinese battery maker CATL (3750 HK: −19.06%), after much worse-than-expected quarterly numbers, reinforced the negative momentum after midweek. Select health care stocks rose strongly after earnings, with the most upside recorded by French biotech Nanobiotix (NANO FP: +34.83%) and Belgium’s biopharma UCB (UCB BB: +33.28%).

In more biotech IPO news, we note last week’s big reversal in the much-touted research platform Iambic Therapeutics (IAM US: −40.11%). After gaining +49% in its first week, the stock now trades at an 11% discount to its October 15 IPO price.

04Performance Monitor

SELECT IPOX® STRATEGIES - PRICE RETURNSAs of October 23, 2026

SELECT IPOX® STRATEGIES - PRICE RETURNS As of October 23, 2026

Index and stock returns in percent. Missing observations are unavailable.
IPOX® StrategyWeekYTD1Y
IPOX® Health InnovationIPHI · USD+2.40%+4.74%+9.73%
GINDEX® Growth Infusion U.S.GNDX · USD+1.29%+16.03%+16.67%
IPOX® Composite U.S.IPXC · USD+0.40%+8.02%+7.59%
IPOX® Global High Dividend 7%USD+0.28%+11.57%+14.09%
IPOX® Alpha Plus ActiveIPXT · USD−0.15%+15.14%+7.32%
IPOX® 100 U.S.* †IPXO · USD · ETF: FPX−0.48%+3.38%+3.58%
IPOX® 100 Europe†IPOE · USD · ETF: FPXE−1.25%−1.53%−1.55%
GINDEX® Growth Infusion InternationalGNDXI · USD−2.31%+5.91%+13.68%
IPOX® Global 50 Super LiquidIPGL50 · USD−3.20%+15.17%+14.68%
IPOX® InternationalIPXI · USD · ETF: FPXI−3.28%+5.93%+6.52%
IPOX® Greater ChinaCNI · USD−4.48%−19.74%−23.74%
IPOX® JapanIPJP · JPY−4.54%+52.36%+71.25%
12 rows

Source: IPOX®

* Basis for CME-traded e-mini IPOX® 100 U.S. Futures (IPOZ6).

† Also available in UCITS format in Europe in EUR (EFPX IM), USD (IPXE LN), and GBP (FPX LN/FPXE LN).

05ECM Review

26 firms went public globally last week, raising a combined $3.24 billion. New listings gained an average of +26.72% from offer price to Friday’s close (median: +2.78%).

26New listings globally
$3.24bnCombined proceeds
+26.72%Average return from offer

In the U.S., protein degradation therapeutics firm Lycia Therapeutics (LYCA US: +66.67%) raised $318 million. Other notable listings in accessible markets included Greek container shipping operator Capital Maritime Finance (CMFC GA: +0.40%, $336 million), South Korean AI cloud provider Elice (0158S0 KS: +4.09%, $145 million), Australian gold miner Wiluna Mining (WMC AU: −23.08%, $123 million) and New Zealand solar-energy-focused Lodestone Energy (LOD NZ: +2.22%, $57 million).

06Outlook

This week, at least six sizable IPOs are set to debut globally. Electronic components maker Precision Manufacturing (2384 HK, $1.36 billion) leads the calendar, followed by industrial robotics technology provider Microintelligence (3275 HK, $91 million).

Elsewhere, Taiwan-founded semiconductor materials firm Mi Material (MIM SP, $109 million), Japanese real estate firm Toggle (652A JP, $86 million), French sports nutrition and equipment retailer N4 Group (ALN4 FP, $56 million), precision engineering solutions provider TEK4 Group ($33 million) and South Korean industrial equipment maker TNE Korea (0053F0 KS, $28 million) are expected to list.

More spin-offs lined up

Spin-off activity also features prominently, with Madison Square Garden Sports planning to separate ice hockey franchise MSG Rangers (MSGR US, estimated valuation: $2.5 billion). The remaining firm is set to be renamed MSG Knicks (MSGK US), housing the basketball franchise at a valuation of about $7.5 billion.

Germany’s Thyssenkrupp industrial logistics unit Tk Accelis, valued at approximately $4 billion, is also lined up.

End of issue 867Back to top ↑